BIOMARKER:

KMT2D mutation

Entrez ID:

Related biomarkers:

‹

›

KMT2D mutation KMT2D mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	KMT2D mutation KMT2D mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
KMT2D mutation KMT2D mutation	Follicular Lymphoma Follicular Lymphoma	KMT2D mutation KMT2D mutation	Follicular Lymphoma Follicular Lymphoma	R-CHOP Resistant: C3 – Early Trials	R-CHOP Resistant: C3 – Early Trials
KMT2D mutation KMT2D mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	KMT2D mutation KMT2D mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	chidamide Resistant: C3 – Early Trials	chidamide Resistant: C3 – Early Trials
KMT2D mutation KMT2D mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	KMT2D mutation KMT2D mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials	ibrutinib Sensitive: C3 – Early Trials
KMT2D mutation KMT2D mutation	Marginal Zone Lymphoma Marginal Zone Lymphoma	KMT2D mutation KMT2D mutation	Marginal Zone Lymphoma Marginal Zone Lymphoma	ibrutinib Resistant: C3 – Early Trials	ibrutinib Resistant: C3 – Early Trials
KMT2D mutation KMT2D mutation	Colorectal Cancer CRC	KMT2D mutation KMT2D mutation	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KMT2D mutation KMT2D mutation	Non Small Cell Lung Cancer NSCLC	KMT2D mutation KMT2D mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KMT2D mutation KMT2D mutation	Colorectal Cancer CRC	KMT2D mutation KMT2D mutation	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KMT2D mutation KMT2D mutation	Cervical Cancer Cervical Cancer	KMT2D mutation KMT2D mutation	Cervical Cancer Cervical Cancer	anlotinib + sintilimab Sensitive: C3 – Early Trials	anlotinib + sintilimab Sensitive: C3 – Early Trials
KMT2D mutation KMT2D mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	KMT2D mutation KMT2D mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	cyclophosphamide + epirubicin Resistant: C3 – Early Trials	cyclophosphamide + epirubicin Resistant: C3 – Early Trials
KMT2D mutation KMT2D mutation	Chronic Lymphocytic Leukemia CLL	KMT2D mutation KMT2D mutation	Chronic Lymphocytic Leukemia CLL	decitabine Sensitive: D – Preclinical	decitabine Sensitive: D – Preclinical
KMT2D mutation KMT2D mutation	Chronic Lymphocytic Leukemia CLL	KMT2D mutation KMT2D mutation	Chronic Lymphocytic Leukemia CLL	chidamide Sensitive: D – Preclinical	chidamide Sensitive: D – Preclinical
KMT2D mutation KMT2D mutation	Chronic Lymphocytic Leukemia CLL	KMT2D mutation KMT2D mutation	Chronic Lymphocytic Leukemia CLL	ibrutinib + chidamide Sensitive: D – Preclinical	ibrutinib + chidamide Sensitive: D – Preclinical
KMT2D mutation KMT2D mutation	Chronic Lymphocytic Leukemia CLL	KMT2D mutation KMT2D mutation	Chronic Lymphocytic Leukemia CLL	ibrutinib + decitabine Sensitive: D – Preclinical	ibrutinib + decitabine Sensitive: D – Preclinical